Jeffrey Lawrence Schwartz
CIK 1702957 · Chief Executive Officer · last filed 2025-09-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$688.98M
Companies
7
Total Filings
17
Lifetime Open-Market Net
-$294.42M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KMTS | Director | 27,030,134 | $23.86 | $644.94M | $0 | 1 | 2025-09-08 |
| RPID | Director | 8,448,860 | $2.06 | $17.40M | $0 | 4 | 2024-05-28 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 3,091,879 | $46.99 | $145.29M | -$320.07M | 8 | 2023-05-25 |
| BCLS Acquisition Corp. (BLSA) Delisted | Chief Executive Officer | 487,500 | $10.04 | $4.89M | $0 | 1 | 2020-10-26 |
| ANNX | 10%+ Owner | 2,841,628 | $4.97 | $14.12M | $40.80M | 1 | 2020-07-28 |
| REPL | 10%+ Owner | 2,338,968 | $5.35 | $12.51M | $45.00M | 1 | 2018-07-26 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | 10%+ Owner | 994,363 | $0.55 | $546.9K | -$60.15M | 1 | 2017-12-19 |
Recent Filings · Page 2 of 2
17 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-10-26 | BCLS Acquisition Corp. (BLSA) Delisted | Grant (A) | +487,500 | $4.88M | EDGAR |
| 2020-07-28 | ANNX | Mixed | +19,449,768 | $40.80M | EDGAR |
| 2020-05-22 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-09-19 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Mixed | +29,125,228 | $10.80M | EDGAR |
| 2019-09-16 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-26 | REPL | Mixed | +17,033,808 | $45.00M | EDGAR |
| 2017-12-19 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Sell (S) | −7,635,282 | -$60.15M | EDGAR |
Showing 11–17 of 17
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.